Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
France
Institut de Cancérologie de l'Ouest, Angers Hôpital Universitaire d'Angers, Angers CHU de Bordeaux, Bordeaux Hôpital Saint-André, Bordeaux Hôpital Neurologique Pierre Wertheimer, Bron Centre Oscar Lambret, Lille Hôpital de la Timone, Marseille Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris IUCT - Claudius Regaud, Toulouse Institut Gustave Roussy, Villejuif Age range
12 Years and older
Last updated November 2025